8-K: Certara Reports Mixed Q4, FY25 Results; Cautious 2026 Outlook

Certara, a global leader in model-informed drug development, reported its fourth quarter and full fiscal year 2025 financial results, alongside its full year 2026 guidance.

Summary

• Full fiscal year 2025 revenue reached $418.8 million, representing 9% year-over-year growth.
• Full fiscal year 2025 Adjusted EBITDA was $134.5 million, a 10% increase year-over-year, with a 32% margin, at the high end of the company's plan.
• Fourth quarter 2025 revenue was $103.6 million, growing 3% compared to the fourth quarter of 2024.
• Fourth quarter 2025 Adjusted EBITDA declined 3% to $32.5 million.
• The company reported a net loss of $5.9 million in Q4 2025, a significant decrease from a net income of $6.6 million in Q4 2024.
• Diluted earnings per share for Q4 2025 was $(0.04), down from $0.04 in Q4 2024.
• Software revenue grew 10% to $46.4 million in Q4 2025, while services revenue decreased 1% to $57.3 million.
• Total bookings for Q4 2025 increased 7% to $155.2 million, driven by a 17% increase in services bookings, though software bookings decreased 6%.
• For full year 2026, Certara expects revenue growth in the range of 0-4%, an Adjusted EBITDA margin of 30-32%, and Adjusted Diluted EPS of $0.44-$0.48.
• Jon Resnick was appointed Chief Executive Officer and a member of the Board of Directors, effective January 1, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with concerning forward guidance. While full-year 2025 performance was solid, the significant Q4 net loss, decline in adjusted EBITDA, and substantially lower 2026 revenue growth outlook suggest underlying challenges and a period of uncertainty.

Positives

• Full fiscal year 2025 revenue grew 9% to $418.8 million.
• Full fiscal year 2025 Adjusted EBITDA increased 10% to $134.5 million, achieving a 32% margin, which was at the high end of the company's plan.
• Q4 2025 software revenue grew 10% to $46.4 million.
• Q4 2025 total bookings increased 7% to $155.2 million, indicating future business momentum.
• Q4 2025 services bookings significantly increased by 17% to $99.1 million, supporting continued revenue momentum.
• Net cash provided by operating activities for FY 2025 was $96.3 million, up from $80.5 million in FY 2024.
• Cash and cash equivalents increased to $189.4 million at December 31, 2025, from $179.2 million at December 31, 2024.
• The appointment of Jon Resnick as Chief Executive Officer and Board Member is expected to sharpen strategic focus and accelerate innovation.

Negatives

• Fourth quarter 2025 Adjusted EBITDA declined 3% to $32.5 million.
• The company reported a net loss of $5.9 million in Q4 2025, a 190% decrease from a net income of $6.6 million in Q4 2024.
• Diluted earnings per share for Q4 2025 was $(0.04), a decrease from $0.04 in Q4 2024.
• Q4 2025 services revenue decreased 1% to $57.3 million.
• Q4 2025 software bookings decreased 6% to $56.1 million, attributed to external factors and execution challenges.
• The full year 2026 revenue growth guidance of 0-4% represents a significant deceleration compared to the 9% growth achieved in FY 2025.
• Higher operating expenses in Q4 2025 were primarily due to increased employee-related costs, equipment and software expenses, professional and consulting expenses, and transaction expenses related to term loan refinancing.

Risks

• Any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development.
• The company's ability to compete within its market.
• Changes or delays in government regulation relating to the biopharmaceutical industry.
• Trends in research and development spending.
• Operational disruptions, funding constraints, and policy changes at the Food and Drug Administration and other government agencies.
• Consolidation within the biopharmaceutical industry.
• The company's ability to successfully increase its customer base, expand relationships and the products and services it provides, and enter new markets.
• The company's ability to retain key personnel or recruit additional qualified personnel.
• Risks related to the mischaracterization of independent contractors.
• Any delays or defects in the release of new or enhanced software or other biosimulation tools.
• Issues relating to implementation, use, and development of artificial intelligence and machine learning in the company's products and services.
• Failure of existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by existing customers.
• Risks related to contracts with government customers and receipt of government grants.
• Risks related to any future acquisitions and other strategic transactions.
• The accuracy of the company's addressable market estimates.
• The company's ability to operate successfully a global business and adverse global economic conditions.
• The company's ability to comply with applicable anti-corruption, trade compliance, and economic sanctions laws and regulations.
• The company's ability to perform its services in accordance with contractual requirements, regulatory standards, and ethical considerations.
• The loss of more than one of the company's major customers.
• The ability or inability of bookings to accurately predict future revenue and the ability to realize anticipated revenue reflected in bookings.
• Lower utilization rates by employees as a result of catastrophic events, including natural disasters and epidemic diseases.
• Disruptions in the operations of third-party providers who host software solutions or any limitations on their capacity or interference with their use.
• Any unauthorized access to or use of customer or other proprietary or confidential data or other breach of cybersecurity measures, compliance with privacy and cybersecurity laws and related contractual requirements.
• The company's ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of services over the internet.
• The company's ability to comply with the terms of any licenses governing the use of third-party open source software.
• The company's ability to adequately enforce or defend its ownership and use of intellectual property and other proprietary rights.
• Any allegations that the company is infringing, misappropriating, or otherwise violating a third party's intellectual property rights.
• Risks related to indebtedness.
• Any additional impairment of goodwill or other intangible assets.

Future Outlook

Certara anticipates 2026 to be a year of transition and investment, with a strategic focus on accelerating innovation across its product portfolio and elevating commercial execution. The company expects end markets to remain stable and aims to drive improving revenue growth throughout the year, positioning itself for sustained long-term growth. Full year 2026 revenue is projected to grow between 0-4%, with an Adjusted EBITDA margin of 30-32% and Adjusted Diluted EPS in the range of $0.44-$0.48.

Management Comments

• Jon Resnick, CEO: "I am excited to join Certara, the market leader in the fast-growing, high-impact fields of AI-enabled biosimulation and model-informed drug development. In my first 60 days, I have been genuinely impressed by the power of our technology, the depth of our customer relationships, and the strength of our people. It's clear that this company and this market opportunity have the foundation required for long-term success. To fully realize our potential, over the course of 2026 we will sharpen our strategic focus, accelerate innovation across our product portfolio, and elevate our commercial execution. It will be a year of transition and investment as we put the right people, processes, and structure in place to position the company to better capture the significant market opportunities and enable the company to drive stronger and sustainable growth."
• John Gallagher, CFO: "Our full year and fourth quarter revenue performance was in-line with our expectations on both a reported and organic basis. Adjusted EBITDA margin was 32% for the year, at the high end of our plan, driven by operating efficiencies while maintaining investment in R&D. As we look forward into 2026, we expect end markets to remain stable, and we anticipate a number of changes and initiatives over the course of 2026 to drive improving revenue growth through the year, and to better position us for sustained long term growth."

Industry Context

StockSavvy.ai notes that Certara operates in the rapidly evolving fields of AI-enabled biosimulation and model-informed drug development, which are critical for accelerating drug discovery and development. The company's strategic focus on innovation and commercial execution in 2026, under new leadership, aligns with broader industry trends emphasizing efficiency and advanced technological integration in biopharmaceutical R&D. The anticipated period of transition and investment reflects the competitive landscape and the need to continuously adapt to technological advancements and market demands in this high-growth sector.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing to provide a direct comparison to industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• No ongoing legal proceedings are mentioned in the filing. A non-recurring employment litigation and settlement expense was noted in the non-GAAP reconciliation for past periods.

Related Party Transactions

• No related party transactions are disclosed in the filing.

Stakeholder Impact

• Shareholders: Potential negative impact on short-term share price due to lower growth guidance and Q4 net loss, but potential long-term benefits from strategic investments and new leadership.
• Employees: Potential impact from reorganization and severance expenses mentioned in non-GAAP adjustments, as the company focuses on 'putting the right people, processes, and structure in place'.
• Customers: Continued focus on accelerating innovation and elevating commercial execution aims to enhance product offerings and customer relationships.
• Creditors: Refinancing of the term loan indicates active management of debt obligations.

Next Steps

• Sharpen strategic focus over the course of 2026.
• Accelerate innovation across the product portfolio over the course of 2026.
• Elevate commercial execution over the course of 2026.
• Put the right people, processes, and structure in place to position the company for stronger and sustainable growth.
• Host a conference call on February 26, 2026, at 8:30 a.m. ET to discuss financial results.

Key Dates

Recommendation

While Certara operates in a high-growth industry with a new CEO focused on strategic improvements, the immediate financial outlook is concerning. The significant slowdown in projected revenue growth for 2026 and the Q4 net loss suggest a period of transition and investment that may impact short-term performance. A 'Hold' recommendation allows investors to observe the execution of the new CEO's strategy and assess if the planned investments translate into stronger, sustainable growth beyond 2026, without exiting a company with long-term potential in a critical sector.

Keywords

Certara, CERT, biosimulation, drug development, model-informed, AI, machine learning, biopharmaceutical, software, services, financial results, earnings, 8-K, Q4 2025, FY 2025, 2026 guidance